Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Margaretha Grind"'
Publikováno v:
Journal of the American College of Cardiology. 41:1445-1451
OBJECTIVES We sought to compare the tolerability and safety of three fixed doses of ximelagatran versus warfarin in patients with nonvalvular atrial fibrillation (NVAF). BACKGROUND Anticoagulants such as warfarin lower the risk of stroke in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb5b8de425383210d19e8d1d484c5e1e
https://doi.org/10.1016/s0735-1097(03)00255-9
https://doi.org/10.1016/s0735-1097(03)00255-9
Publikováno v:
Clinical Drug Investigation. 9:67-71
12 healthy male volunteers participated in this open, randomised, crossover study. On 2 study days at least 6 days apart the volunteers were given a single oral dose of lansoprazole 30mg with or without a standardised breakfast. When lansoprazole was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4233b7542dba68851ba5b58e95a89385
https://doi.org/10.2165/00044011-199509020-00002
https://doi.org/10.2165/00044011-199509020-00002
Publikováno v:
European heart journal. 28(6)
Aim To test the hypothesis that stroke and systemic embolic events (SEE) in the Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation (SPORTIF) III and V trials were related to blood pressure, and that differences in event rates (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1706882c036be3ba67ccddbfe9c4b5cc
https://pubmed.ncbi.nlm.nih.gov/17289744
https://pubmed.ncbi.nlm.nih.gov/17289744
Autor:
Rhiddian Shelton, Nikolay P. Nikitin, Lars Frison, John G.F. Cleland, Margaretha Grind, Sarah Ford
Publikováno v:
European journal of heart failure. 9(6-7)
Background: Patients with atrial fibrillation (AF) who also have heart failure have a worse outcome but the diagnosis of heart failure is often missed. Aim: To compare the effects of warfarin and ximelagatran on morbidity and mortality in patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b77b253093a9540e62a80f8e7af379fb
https://pubmed.ncbi.nlm.nih.gov/17360232
https://pubmed.ncbi.nlm.nih.gov/17360232
Autor:
Maria Wollbratt, Michael Wolzt, Margaretha Grind, Mia Svensson, Karin Wåhlander, Ulf Eriksson
Publikováno v:
European journal of clinical pharmacology. 59(7)
To investigate the influence of nonvalvular atrial fibrillation (NVAF) on the pharmacokinetic (PK) properties of the oral direct thrombin inhibitor ximelagatran and its active form, melagatran. In an open study, 12 patients with persistent NVAF and 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f527d5c1c50cedfe92371353900f493
https://pubmed.ncbi.nlm.nih.gov/12955372
https://pubmed.ncbi.nlm.nih.gov/12955372
Publikováno v:
Journal of the American College of Cardiology. 41(9)
We sought to compare the tolerability and safety of three fixed doses of ximelagatran versus warfarin in patients with nonvalvular atrial fibrillation (NVAF).Anticoagulants such as warfarin lower the risk of stroke in patients with NVAF. Ximelagatran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4415e947fc2891a65fdb9d2147ff7a3a
https://pubmed.ncbi.nlm.nih.gov/12742279
https://pubmed.ncbi.nlm.nih.gov/12742279
Autor:
Mia Svensson, Michael Wolzt, Troy C. Sarich, Margaretha Grind, Stig L. Boström, Karin Wåhlander
Publikováno v:
Pathophysiology of haemostasis and thrombosis. 33(2)
This study investigated the pharmacodynamic effects of the oral direct thrombin inhibitor ximelagatran on platelet activation and thrombin generation in patients with nonvalvular atrial fibrillation. Using an open, group-matched study design, the eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f468eab9f053c1b795515eb177d5f08a
https://pubmed.ncbi.nlm.nih.gov/14624047
https://pubmed.ncbi.nlm.nih.gov/14624047
Publikováno v:
Clinical pharmacology and therapeutics. 54(4)
The potential effects of extended-release felodipine on the pharmacokinetics and pharmacodynamics of warfarin were studied in a double-blind crossover study in 12 healthy men. Warfarin dosage was adjusted to achieve stable subtherapeutic anticoagulat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73564e42823a2fe45c6d0eadc17a6561
https://pubmed.ncbi.nlm.nih.gov/8222480
https://pubmed.ncbi.nlm.nih.gov/8222480
Autor:
Lars Frison, Jay Horrow, S Partridge, Margaretha Grind, Hans-Christoph Diener, Jonathan L. Halperin, M Nevinson, Bertil Olsson, Alec Vahanian, Palle Petersen, Gregory W. Albers
Publikováno v:
JAMA. 293:690
Context Inpatients with nonvalvular atrial fibrillation, warfarin prevents ischemic stroke, but dose adjustment, coagulation monitoring, and bleeding limit its use. Objective To compare the efficacy of the oral direct thrombin inhibitor ximelagatran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ccf834cefd52d59df449d27cdad6233
https://doi.org/10.1001/jama.293.6.690
https://doi.org/10.1001/jama.293.6.690
Publikováno v:
Psychopharmacology. 98:304-309
The tolerability and pharmacokinetics of remoxipride were studied in 18 healthy normal male volunteers. Increasing oral doses of 0.5-100 mg were given to eight male volunteers in one study (study I). In addition, an intravenous (IV) infusion of 20 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43e4a426c663b2e693b8a3cc6587ecc4
https://doi.org/10.1007/bf00451679
https://doi.org/10.1007/bf00451679